journal article·2023-09Open access

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells

Chan Liao, Yajie Wang, Yanjie Huang, Yanting Duan, Yan Liang, Jiangqing Chen, Jie Jiang, Kai Shang, Chun Zhou, Ying Gu, Nan Liu, Xun Zeng, Xiaofei Gao, Yongmin Tang, Jie Sun

Advanced Science· Volume 10· Issue 27

Abstract

Abstract The robust and stable expression of CD38 in T‐cell acute lymphoblastic leukemia (T‐ALL) blasts makes CD38 chimeric antigen receptor (CAR)‐T/natural killer (NK) a potential therapy for T‐ALL. However, CD38 expression in normal T/NK cells causes fratricide of CD38 CAR‐T/NK cells. Here a “2‐in‐1” gene editing strategy is developed to generate fratricide‐resistant locus‐specific CAR‐T/NK cells. CD38‐specific CAR is integrated into the disrupted CD38 locus by CRISPR/Cas9, and CAR is placed under the control of either endogenous CD38 promoter (CD38KO/KI) or exogenous EF1α promoter (CD38KO/KIEF1α). CD38 knockout reduces fratricide and allows the expansion of CAR‐T cells. Meanwhile, CD38KO/KIEF1α results in higher CAR expression than CD38KO/KI in both CAR‐T and CAR‐NK cells. In a mouse T‐ALL model, CD38KO/KIEF1α CAR‐T cells eradicate tumors better than CD38KO/KI CAR‐T cells. Surprisingly, CD38KO/KI CAR‐NK cells show superior tumor control than CD38KO/KIEF1α CAR‐NK cells. Further investigation reveals that endogenous regulatory elements in NK cells lead to higher expression of CD38 CAR than in T cells, and the expression levels of CAR affect the therapeutic outcome of CAR‐T and CAR‐NK cells differently. Therefore, these results support the efficacy of CD38 CAR‐T/NK against T‐ALL and demonstrate that the “2‐in‐1” strategy can resolve fratricide and enhance tumor eradication, paving the way for clinical translation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: CAR-T cell therapy research · Silicon Carbide Semiconductor Technologies · Radio Frequency Integrated Circuit Design

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Hematology‐oncology Children's Hospital Zhejiang University School of Medicine Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province National Clinical Research Center for Child Health Hangzhou 310003 China

Liangzhu Laboratory Zhejiang University Medical Center Hangzhou 311121 China

Bone Marrow Transplantation Center of the First Affiliated Hospital and Department of Cell Biology Zhejiang University School of Medicine Hangzhou 310058 China

Institute of Hematology Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy Hangzhou 310058 China

Key Laboratory of Structural Biology of Zhejiang Province School of Life Sciences Westlake University Hangzhou 310058 China

School of Basic Medical Sciences Fudan University Shanghai 200032 China

School of Public Health and Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou 310058 China

Institute of Genetics, Zhejiang University and Department of Genetics Zhejiang University school of medicine Hangzhou 310058 China

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases First Affiliated Hospital Zhejiang University School of Medicine Hangzhou 310058 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province

References (55)

Show source-provided references
1. 10.1038/nrc.2016.6310.1038/nrc.2016.63 ↗
2. 10.1002/gcc.2241610.1002/gcc.22416 ↗
3. 10.1111/imr.1223710.1111/imr.12237 ↗
4. 10.1016/S1535-6108(02)00018-110.1016/S1535-6108(02)00018-1 ↗
5. 10.1016/S1470-2045(08)70314-010.1016/S1470-2045(08)70314-0 ↗
6. 10.1200/JCO.2005.03.42610.1200/JCO.2005.03.426 ↗
7. 10.1172/JCI8001010.1172/JCI80010 ↗
8. 10.1056/NEJMra170616910.1056/NEJMra1706169 ↗
9. 10.1200/JCO.2014.56.202510.1200/JCO.2014.56.2025 ↗
10. 10.1186/s13045-019-0801-y10.1186/s13045-019-0801-y ↗
11. 10.1038/s41375-018-0285-810.1038/s41375-018-0285-8 ↗
12. 10.1038/s41591-018-0201-910.1038/s41591-018-0201-9 ↗
13. 10.1182/blood-2002-08-243810.1182/blood-2002-08-2438 ↗
14. 10.1182/blood-2017-01-76132010.1182/blood-2017-01-761320 ↗
15. 10.1080/2162402X.2017.140789810.1080/2162402X.2017.1407898 ↗
16. 10.1038/leu.2015.31110.1038/leu.2015.311 ↗
17. 10.1182/blood-2018-10-88294410.1182/blood-2018-10-882944 ↗
18. 10.1038/nm.444410.1038/nm.4444 ↗
19. 10.1038/s41375-018-0065-510.1038/s41375-018-0065-5 ↗
20. 10.1182/bloodadvances.201700992810.1182/bloodadvances.2017009928 ↗
21. 10.1016/j.ymthe.2022.09.00310.1016/j.ymthe.2022.09.003 ↗
22. 10.1038/nm.444110.1038/nm.4441 ↗
23. 10.1126/scitranslmed.aaw941410.1126/scitranslmed.aaw9414 ↗
24. 10.1159/00005876910.1159/000058769 ↗
25. 10.1136/jitc-2020-00063010.1136/jitc-2020-000630 ↗
26. 10.3390/ijms2120768510.3390/ijms21207685 ↗
27. 10.1038/leu.2011.20510.1038/leu.2011.205 ↗
28. 10.3324/haematol.2020.27190810.3324/haematol.2020.271908 ↗
29. 10.1158/1078-0432.CCR-18-255910.1158/1078-0432.CCR-18-2559 ↗
30. 10.18632/oncotarget.2262610.18632/oncotarget.22626 ↗
31. You F. · Am. J. Cancer Res. · 2019 · 9 · 64
32. 10.1038/leu.2017.810.1038/leu.2017.8 ↗
33. 10.3324/haematol.2015.13762010.3324/haematol.2015.137620 ↗
34. 10.1182/blood.202000620010.1182/blood.2020006200 ↗
35. 10.1038/nature2140510.1038/nature21405 ↗
36. 10.3389/fphar.2015.0002110.3389/fphar.2015.00021 ↗
37. 10.1186/s13045-020-00998-910.1186/s13045-020-00998-9 ↗
38. 10.1007/s13238-017-0415-510.1007/s13238-017-0415-5 ↗
39. 10.3389/fimmu.2020.59795910.3389/fimmu.2020.597959 ↗
40. 10.1097/HS9.000000000000059610.1097/HS9.0000000000000596 ↗
41. 10.1038/cti.2016.7310.1038/cti.2016.73 ↗
42. 10.1038/s41423-019-0355-510.1038/s41423-019-0355-5 ↗
43. 10.1111/j.1365-2141.2010.08297.x10.1111/j.1365-2141.2010.08297.x ↗
44. 10.1186/s13046-022-02421-210.1186/s13046-022-02421-2 ↗
45. 10.1038/nm.383810.1038/nm.3838 ↗
46. 10.1038/s41577-019-0224-610.1038/s41577-019-0224-6 ↗
47. 10.1038/cmi.2009.510.1038/cmi.2009.5 ↗
48. 10.1038/s41375-020-0793-110.1038/s41375-020-0793-1 ↗
49. 10.1038/s41591-018-0290-510.1038/s41591-018-0290-5 ↗
50. 10.1016/j.ymthe.2022.08.01810.1016/j.ymthe.2022.08.018 ↗
51. 10.1002/smtd.20210007110.1002/smtd.202100071 ↗
52. 10.1016/j.cell.2019.05.03110.1016/j.cell.2019.05.031 ↗
53. 10.1038/s41467-021-27729-z10.1038/s41467-021-27729-z ↗
54. 10.1038/s41592-021-01282-510.1038/s41592-021-01282-5 ↗
55. 10.1038/s41467-017-02525-w10.1038/s41467-017-02525-w ↗